Home > Healthcare > Medical Devices > Diagnostic Devices > central nervous system biomarkers market
Get a free sample of Central Nervous System Biomarkers Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Central Nervous System Biomarkers Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The central nervous system biomarkers industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced devices based on different technologies is a key market strategy. Some of the leading industry players including F. Hoffmann-La Roche Ltd, Novartis AG, and Thermo Fisher Scientific, Inc, among others have a notable presence in the market.
Some of the eminent market participants operating in the central nervous system biomarkers industry include:
North America central nervous system biomarkers industry reached USD 2.3 billion in 2023 and is expected to register a commendable CAGR from 2024-2032 due to the presence of the world's leading research institutions focused on neuroscience and biomarker development in the region.
The safety biomarker segment recorded USD 2.5 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to their significance in clinical trials to monitor and assess the safety profile of new drugs.
Central nervous system biomarkers market size was USD 5.6 billion in 2023 and is expected to register 8.1% CAGR from 2024-2032 owing to the increasing prevalence of neurological disorders worldwide.
F. Hoffmann-La Roche Ltd, G-Biosciences, Illumina, Inc., Merck KGaA, Myriad Genetics, Inc., Novartis AG, PerkinElmer Inc., Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific Inc., are some of the major central nervous system biomarkers companies worldwide.